{"id":850859,"date":"2025-05-14T08:07:10","date_gmt":"2025-05-14T12:07:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\/"},"modified":"2025-05-14T08:07:10","modified_gmt":"2025-05-14T12:07:10","slug":"newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\/","title":{"rendered":"NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NAARDEN, The Netherlands and MIAMI, May  14, 2025  (GLOBE NEWSWIRE) &#8212; NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or \u201cNewAmsterdam\u201d or the \u201cCompany\u201d), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (\u201cCVD\u201d) with elevated low-density lipoprotein cholesterol (\u201cLDL-C\u201d), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer of NewAmsterdam Pharma, will participate in a fireside chat at the 2025 RBCCM Global Healthcare Conference on Tuesday, May 20, 2025 at 10:00 a.m. ET.<\/p>\n<p>A live webcast of the fireside chat will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available on the Company\u2019s website.<\/p>\n<p>\n        <strong>About NewAmsterdam<\/strong>\n      <\/p>\n<p>NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.<\/p>\n<p>\n        <strong>Company Contact<\/strong><br \/>\n        <br \/>Matthew Philippe<br \/>P: 1-917-882-7512<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5DM7L4ddBJzZ0Do3Rrlr6xav5YPAFfYxUOGEjQBCbn8h_OvZFK66A11S31zx_5W9pWSUbdmoeex9ETGGNElFDNs50w-FymlKMEwJ9oe4KrLGBCc-h4sMn0ivF8V7nVZYjrkHjt8ngCjxViB1AqiF8w==\" rel=\"nofollow\" target=\"_blank\">matthew.philippe@newamsterdampharma.com<\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Spectrum Science on behalf of NewAmsterdam<br \/>Jaryd Leady<br \/>P: 1-856-803-7855<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Zf2HULThcSyrByLB55xI4MhmF45x-vR67Fl1MVXjKwS2-WPorwd20gBzh7QnADULlUsWcV5mGgAH2ze9HAGaim6PZZgFvHJKFmyGNopOsI3NGMYQT7Jo05um0ztFjVRv\" rel=\"nofollow\" target=\"_blank\">jleady@spectrumscience.com<\/a><\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Precision AQ on behalf of NewAmsterdam<br \/>Austin Murtagh<br \/>P: 1-212-698-8696 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=g30JBQH0Sc-aIb0pKAPC4ZeeKYN2VETfRQSRPY9l-p8Mw1NRYnfOy3GWvgckn6404tLr0ya-DoHM-7Ct3nSaIDX9-KDpQaqf7XS2MsYMAM7Z0DtrcfAs0T0MZqAG8Y1W\" rel=\"nofollow\" target=\"_blank\">austin.murtagh@precisionaq.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MDcxMiM2OTM5MjEwIzIyNTAzNDE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjMxYjEyYTgtYzFkOC00ZmY0LTliODktNjczNThmN2I1MjkwLTEyNjE4OTQtMjAyNS0wNS0xNC1lbg==\/tiny\/NewAmsterdam-Pharma-N-V-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NAARDEN, The Netherlands and MIAMI, May 14, 2025 (GLOBE NEWSWIRE) &#8212; NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or \u201cNewAmsterdam\u201d or the \u201cCompany\u201d), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (\u201cCVD\u201d) with elevated low-density lipoprotein cholesterol (\u201cLDL-C\u201d), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer of NewAmsterdam Pharma, will participate in a fireside chat at the 2025 RBCCM Global Healthcare Conference on Tuesday, May 20, 2025 at 10:00 a.m. ET. A live webcast of the fireside chat will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-850859","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NAARDEN, The Netherlands and MIAMI, May 14, 2025 (GLOBE NEWSWIRE) &#8212; NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or \u201cNewAmsterdam\u201d or the \u201cCompany\u201d), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (\u201cCVD\u201d) with elevated low-density lipoprotein cholesterol (\u201cLDL-C\u201d), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer of NewAmsterdam Pharma, will participate in a fireside chat at the 2025 RBCCM Global Healthcare Conference on Tuesday, May 20, 2025 at 10:00 a.m. ET. A live webcast of the fireside chat will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available &hellip; Continue reading &quot;NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-14T12:07:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MDcxMiM2OTM5MjEwIzIyNTAzNDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference\",\"datePublished\":\"2025-05-14T12:07:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\\\/\"},\"wordCount\":281,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MDcxMiM2OTM5MjEwIzIyNTAzNDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\\\/\",\"name\":\"NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MDcxMiM2OTM5MjEwIzIyNTAzNDE=\",\"datePublished\":\"2025-05-14T12:07:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MDcxMiM2OTM5MjEwIzIyNTAzNDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MDcxMiM2OTM5MjEwIzIyNTAzNDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference - Market Newsdesk","og_description":"NAARDEN, The Netherlands and MIAMI, May 14, 2025 (GLOBE NEWSWIRE) &#8212; NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or \u201cNewAmsterdam\u201d or the \u201cCompany\u201d), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (\u201cCVD\u201d) with elevated low-density lipoprotein cholesterol (\u201cLDL-C\u201d), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer of NewAmsterdam Pharma, will participate in a fireside chat at the 2025 RBCCM Global Healthcare Conference on Tuesday, May 20, 2025 at 10:00 a.m. ET. A live webcast of the fireside chat will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available &hellip; Continue reading \"NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-14T12:07:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MDcxMiM2OTM5MjEwIzIyNTAzNDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference","datePublished":"2025-05-14T12:07:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\/"},"wordCount":281,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MDcxMiM2OTM5MjEwIzIyNTAzNDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\/","name":"NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MDcxMiM2OTM5MjEwIzIyNTAzNDE=","datePublished":"2025-05-14T12:07:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MDcxMiM2OTM5MjEwIzIyNTAzNDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MDcxMiM2OTM5MjEwIzIyNTAzNDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-present-at-the-2025-rbccm-global-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/850859","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=850859"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/850859\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=850859"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=850859"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=850859"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}